Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?

In a surprising turn of events, AstraZeneca and Bristol Myers Squibb are reportedly engaging in negotiations for a potential mega-merger that could rank among the largest in pharmaceutical history. However, the industry's history of successful large-scale acquisitions is not without its share of challenges. To gain insight into this potential acquisition, a Post-Hoc Live emergency session was held with Jeremy Levin, a biopharma leader with extensive experience in dealmaking at Bristol Myers, as well as a former CEO of Teva.

The discussion took place via a livestream, which is now available on YouTube, as well as through Spotify and Apple Podcasts.

During the session, the focus was on the motivations behind both companies' interest in a potential merger. A key question that remains unanswered is why Bristol Myers would seek to acquire AstraZeneca, and conversely, why AstraZeneca would be interested in Bristol Myers. The conversation also delved into the ways in which such large-scale acquisitions disrupt organizational structures, and what this could mean for antitrust regulations during the Trump administration.

The discussion offered a comprehensive look at the various aspects of the proposed deal, providing a unique perspective from a seasoned industry insider like Jeremy Levin.